ConductScience.org, home

Paper12372721

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.

Schwartz JD and 3 others. Lancet Oncol, 2002. Cited by 220 papers, by iCite.

Cite this record

ConductScience Library. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Papers, record 12372721. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12372721

Download JSON
Disease
hepatocellular carcinoma478 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
PubMed
Journal
Lancet Oncol
PubMed
Year
2002
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
220
iCite
Relative citation ratio, by iCite
5.21
iCite
Revised in PubMed
2019-10-25
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schwartz JDJonathan D
2Schwartz MMyron
3Mandeli JJohn
4Sung MMax

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Chemoembolization, Therapeutic
Chemotherapy, Adjuvant
Humans
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Research Design
Survival Analysis

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06041477Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCCResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by90

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 220 citations.

PMIDTitleJournalYearIn PapersSource
41935630IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection.JHEP Rep2026https://conductscience.org/library/papers/41935630PubMed
41024879Postoperative adjuvant management in hepatocellular carcinoma: A review of therapeutic efficacy and prognostic outcomes.World J Hepatol2025https://conductscience.org/library/papers/41024879PubMed
39944245Novel online calculator to predict reduced risk of early recurrence from adjuvant transarterial chemoembolisation for patients with hepatocellular carcinoma.eGastroenterology2023https://conductscience.org/library/papers/39944245PubMed
39648422A Review on Hepatoprotective Effect of Chrysin: Preclinical Implications and Molecular Cascades Came into Focus.Curr Diabetes Rev2026https://conductscience.org/library/papers/39648422PubMed
39290260Development and validation of a nomogram for predicting microvascular invasion and evaluating the efficacy of postoperative adjuvant transarterial chemoembolization.Heliyon2024https://conductscience.org/library/papers/39290260PubMed
38322198Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.Hepatobiliary Surg Nutr2024https://conductscience.org/library/papers/38322198PubMed
38164269Survival effects of postoperative adjuvant TACE in early-HCC patients with microvascular invasion: A multicenter propensity score matching.J Cancer2024https://conductscience.org/library/papers/38164269PubMed
381071862023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations.J Clin Exp Hepatol2024https://conductscience.org/library/papers/38107186PubMed
37864725Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.Hepatol Int2024https://conductscience.org/library/papers/37864725PubMed
37696656Mouse Models of Metastasis and Dormancy.Cold Spring Harb Perspect Med2024https://conductscience.org/library/papers/37696656PubMed
37287040Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study.Radiat Oncol2023https://conductscience.org/library/papers/37287040PubMed
37070467Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.Ann Med2023https://conductscience.org/library/papers/37070467PubMed
37052853DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis.Cell Oncol (Dordr)2023https://conductscience.org/library/papers/37052853PubMed
36525610Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.J Clin Oncol2023https://conductscience.org/library/papers/36525610PubMed
36050540Vessels that encapsulate tumor clusters (VETC) pattern predicts the efficacy of adjuvant TACE in hepatocellular carcinoma.J Cancer Res Clin Oncol2023https://conductscience.org/library/papers/36050540PubMed
35686094The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy.Front Oncol2022https://conductscience.org/library/papers/35686094PubMed
35070063Neoadjuvant treatment strategies for hepatocellular carcinoma.World J Gastrointest Surg2021https://conductscience.org/library/papers/35070063PubMed
34641921
Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.
J Hematol Oncol2021https://conductscience.org/library/papers/34641921PubMed
34097307Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.Hepatology2021https://conductscience.org/library/papers/34097307PubMed
33854587A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma.J Cancer2021https://conductscience.org/library/papers/33854587PubMed

See all 90 cited byDownload CSV of cited by

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
FLUOROURACILCHEMBL185Results1https://conductscience.org/library/drugs/CHEMBL185ChEMBL
LEVOLEUCOVORINCHEMBL1908841Results1https://conductscience.org/library/drugs/CHEMBL1908841ChEMBL
OXALIPLATINCHEMBL414804Results1https://conductscience.org/library/drugs/CHEMBL414804ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12372721

GET https://conductscience.org/api/papers/v1/12372721/cited_by?page=2